Analysts expect Biomarin Pharmaceutical to report an earnings per share (EPS) of $0.53.
Anticipation surrounds Biomarin Pharmaceutical's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
Historical Earnings Performance
Last quarter the company beat EPS by $0.51, which was followed by a 2.69% increase in the share price the next day.
Here's a look at Biomarin Pharmaceutical's past performance and the resulting price change:
Quarter
Q2 2025
Q1 2025
Q4 2024
Q3 2024
EPS Estimate
0.93
0.71
0.74
0.52
EPS Actual
1.44
1.13
0.92
0.91
Price Change %
3.00
-1.00
5.00
-5.00
Biomarin Pharmaceutical Share Price Analysis
Shares of Biomarin Pharmaceutical were trading at $54.55 as of October 23. Over the last 52-week period, shares are down 22.15%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
Insights Shared by Analysts on Biomarin Pharmaceutical
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Biomarin Pharmaceutical.
Analysts have given Biomarin Pharmaceutical a total of 4 ratings, with the consensus rating ...